一名患有全般性的年轻男性患上帕拉曼尼尔诱导的触角症
Kelsey Kenaan1, Mohsin Zafar2, Ronnie Bond2
1Edward Via College of Osteopathic Medicine, Auburn, AL.
HCA healthcare journal of medicine
|July 10, 2023
概括
佩拉曼奈尔是一种抗药物,可能会引起神经精神病的副作用,如情绪变化. 在患有泛性强力-克隆性发作的患者中,Perampanel的停用和重新引入与情绪不稳定性和触角性相关.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学 是一个学科.
- 神经学 神经学
背景情况:
- 佩拉曼奈尔是一种较新的抗药物,向谷氨酸受体.
- 它的精确治疗机制尚不清楚.
- 报告了神经精神病学的副作用,包括情绪失调和精神病.
研究的目的:
- 描述一种可能与Perampanel相关的神经精神病学副作用的情况.
- 探索这些不良事件的可能机制.
主要方法:
- 一个32岁的男性的病例报告,患有普遍的强力克隆性发作.
- 在添加Perampanel和随后的戒断/恢复后观察神经精神症状.
主要成果:
- 患者经历了Perampanel启动后的情绪不稳定和情绪失调.
- 在Perampanel重新引入后,症状复发,包括在情绪上下文中的运动软弱.
- 这些症状表明Perampanel和触发性障碍之间存在潜在的联系.
结论:
- 佩拉曼奈尔可能会诱导显著的神经精神病学副作用.
- 患者的症状可能源于Perampanel与背下核路径之间的相互作用.
- 需要进一步的研究来阐明Perampanel的复杂机制和副作用概况.
相关概念视频
Antiepileptic Drugs: Glutamate Antagonists
427
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
427
Seizures: Classification
426
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
426
Antiepileptic Drugs: Potassium Channel Activators
215
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
215
Arteries of the Lower Limbs
215
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
215
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
349
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
349
Antiepileptic Drugs: GABAergic Pathway Potentiators
467
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
467


